14.31
-2.07(-12.64%)
Currency In USD
| Previous Close | 16.38 |
| Open | 16.02 |
| Day High | 16.02 |
| Day Low | 13.62 |
| 52-Week High | 25.19 |
| 52-Week Low | 7.26 |
| Volume | 140,419 |
| Average Volume | 168,007 |
| Market Cap | 631.42M |
| PE | -8.57 |
| EPS | -1.67 |
| Moving Average 50 Days | 12.85 |
| Moving Average 200 Days | 14.21 |
| Change | -2.07 |
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
GlobeNewswire Inc.
Jun 06, 2025 3:00 PM GMT
Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
GlobeNewswire Inc.
Jun 04, 2025 11:00 AM GMT
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a pro
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicin